^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AC1Q3QWB

    i
    Other names: AC1Q3QWB, AQB
    Company:
    Tianjin Medical University General Hospital
    Drug class:
    HOTAIR inhibitor
    1year
    Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer. (PubMed, Cancer Lett)
    Our results advocate AQB, a recently discovered small-molecule inhibitor, as a promising agent against EC cells. When combined with TAZ, it offers a novel therapeutic strategy for EC treatment.
    Journal
    |
    HOTAIR (HOX Transcript Antisense RNA) • SOX17 (SRY-Box Transcription Factor 17) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    Tazverik (tazemetostat) • AC1Q3QWB